文献速递生殖医学

不同胚胎阶段活检在微阵列比较基因组杂交植入前遗传学诊断与筛查中的临床结局分析

[Analysis of clinical outcomes of different embryo stage biopsy in array comparative genomic hybridization based preimplantation genetic diagnosis and screening].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2017-01-01

回顾性分析2011年7月至2015年8月南京医科大学第一附属医院381个PGD/PGS周期,比较卵裂期与囊胚期活检的临床结局。array-CGH明确诊断胚胎比例达96.9%~99.1%。PGD周期中囊胚期活检的每移植周期活产率和每活检周期活产率均显著高于卵裂期活检(P均<0.01);PGS周期中两组活产率无显著差异(P均>0.05)。

要点

  • array-CGH在PGD/PGS中的明确诊断胚胎比例达96.9%~99.1%。
  • PGD周期中囊胚期活检活产率显著高于卵裂期活检(P均<0.01)。
  • PGS周期中两种活检活产率无显著差异(P均>0.05)。

核心结论

  • array-CGH技术在PGD/PGS中具有高诊断率,可获得理想的临床活产率。
  • PGD周期中囊胚期活检活产率显著高于卵裂期活检,囊胚期活检效率更好。

研究设计与样本

  • 回顾性分析2011年7月至2015年8月南京医科大学第一附属医院381个PGD/PGS周期。
  • PGD 320个周期:卵裂期活检156个周期、囊胚期活检164个周期。
  • PGS 61个周期:卵裂期活检23个周期、囊胚期活检38个周期。
  • 活检标本采用单细胞全基因组扩增结合array-CGH技术行染色体拷贝数分析,所有移植周期均采用单胚胎移植。

主要发现

  • array-CGH在PGD/PGS中的明确诊断胚胎比例达96.9%~99.1%。
  • PGD周期中,卵裂期活检每移植周期活产率50.0%(58/116)、每活检周期活产率37.2%(58/156)。
  • PGD周期中,囊胚期活检每移植周期活产率67.5%(85/126)、每活检周期活产率51.8%(85/164),均高于卵裂期活检(P均<0.01)。
  • PGS周期中,卵裂期活检每移植周期活产率和每活检周期活产率均为34.8%(8/23)。
  • PGS周期中,囊胚期活检每移植周期活产率和每活检周期活产率均为42.1%(16/38),与卵裂期活检比较差异均无统计学意义(P均>0.05)。

关键数值与推荐

  • array-CGH在PGD/PGS中的明确诊断胚胎比例达96.9%~99.1%。
  • PGD周期中囊胚期活检每移植周期活产率67.5%(85/126)vs 卵裂期活检50.0%(58/116),P<0.01。
  • PGD周期中囊胚期活检每活检周期活产率51.8%(85/164)vs 卵裂期活检37.2%(58/156),P<0.01。
  • PGS周期中囊胚期活检每移植周期活产率42.1%(16/38)vs 卵裂期活检34.8%(8/23),P>0.05。
  • PGS周期中囊胚期活检每活检周期活产率42.1%(16/38)vs 卵裂期活检34.8%(8/23),P>0.05。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficiency of the application of array comparative genomic hybridization (array-CGH) in preimplantation genetic diagnosis or screening (PGD/PGS), and compare the clinical outcomes of different stage embryo biopsy. Methods: The outcomes of 381 PGD/PGS cycles referred in the First Affiliated Hospital of Nanjing Medical University from July 2011 to August 2015 were retrospectively analyzed. There were 320 PGD cycles with 156 cleavage-stage-biopsy cycles and 164 trophectoderm-biopsy cycles, 61 PGS cycles with 23 cleavage-stage-biopsy cycles and 38 trophectoderm-biopsy cycles. Chromosomal analysis was performed by array-CGH technology combined with whole genome amplification. Single embryo transfer was performed in all transfer cycles. Live birth rate was calculated as the main clinical outcomes. Results: The embryo diagnosis rate of PGD/PGS by array-CGH were 96.9%-99.1%. In PGD biopsy cycles, the live birth rate per embryo transfer cycle and live birth rate per embryo biopsy cycle were 50.0%(58/116) and 37.2%(58/156) in cleavage-stage-biopsy group, 67.5%(85/126) and 51.8%(85/164) in trophectoderm-biopsy group (both P<0.01). In PGS biopsy cycles, the live birth rate per embryo transfer cycle and live birth rate per embryo biopsy cycle were the same as 34.8%(8/23) in cleavage-stage-biopsy group, the same as 42.1%(16/38) in trophectoderm-biopsy group (both P>0.05). Conclusions: High diagnosis rate and idea live birth rate are achieved in PGD/PGS cycles based on array-CGH technology. The live birth rate of trophectoderm-biopsy group is significantly higher than that of cleavage-stage-biopsy group in PGD cycles; the efficiency of trophectoderm-biopsy is better. 目的: 探讨微阵列比较基因组杂交(array-CGH)技术在胚胎植入前遗传学诊断或胚胎植入前遗传学筛查(PGD/PGS)中的应用效果及不同胚胎阶段活检的临床结局的差异。 方法: 回顾性分析2011年7月至2015年8月在南京医科大学第一附属医院进行PGD/PGS治疗的381个周期,其中,PGD 320个周期,采用卵裂期活检156个周期、囊胚期活检164个周期;PGS 61个周期,采用卵裂期活检23个周期、囊胚期活检38个周期。活检标本采用单细胞全基因组扩增结合array-CGH技术行染色体拷贝数分析。所有移植周期均采用单胚胎移植,以活产率作为主要临床结局的评价指标。 结果: array-CGH技术在PGD/PGS中的明确诊断胚胎比例达96.9%~99.1%。PGD活检周期中,卵裂期活检的每移植周期活产率和每活检周期活产率分别为50.0%(58/116)、37.2%(58/156),而囊胚期活检者分别为67.5%(85/126)、51.8%(85/164),分别比较,差异均有统计学意义(P均<0.01)。PGS活检周期中,卵裂期活检的每移植周期活产率和每活检周期活产率均为34.8%(8/23),而囊胚期活检者均为42.1%(16/38),分别比较,差异均无统计学意义(P均>0.05)。 结论: array-CGH技术在PGD/PGS中的应用具有高诊断率,基于array-CGH技术的PGD/PGS可获得理想的临床活产率。在PGD周期中,囊胚期活检比卵裂期活检具有更高的活产率。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Shen JD, Wu W, Shu L, et al. [Analysis of clinical outcomes of different embryo stage biopsy in array comparative genomic hybridization based preimplantation genetic diagnosis and screening]. Zhonghua Fu Chan Ke Za Zhi. 2017. PMID: 29325267. doi:10.3760/cma.j.issn.0529-567x.2017.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。